NCCN Task Force Report: Estrogen receptor and progesterone receptor testing in breast cancer by immunohistochemistry

137Citations
Citations of this article
84Readers
Mendeley users who have this article in their library.

Abstract

The NCCN Task Force on Estrogen Receptor and Progesterone Receptor Testing in Breast Cancer by Immunohistochemistry was convened to critically evaluate the extent to which the presence of the estrogen receptor (ER) and progesterone receptor (PgR) biomarkers in breast cancer serve as prognostic and predictive factors in the adjuvant and metastatic settings, and the ability of immunohistochemical (IHC) detection of ER and PgR to provide an accurate assessment of the expression of these biomarkers in breast cancer tumor tissue. The task force is a multidisciplinary panel of 13 experts in breast cancer who are affiliated with NCCN member institutions and represent the disciplines of pathology, medical oncology, radiation oncology, surgical oncology, and biostatistics. The main overall conclusions of the task force are ER is a strong predictor of response to endocrine therapy; ER status of all samples of invasive breast cancer or ductal carcinoma in situ (DCIS) should be evaluated by IHC; IHC measurements of PgR, although not as important clinically as ER, can provide useful information and should also be performed on all samples of invasive breast cancer or DCIS; IHC is the main testing strategy for evaluating ER and PgR in breast cancer and priority should be given to improve the quality of IHC testing methodologies; all laboratories performing IHC assays of ER and PgR should undertake formal validation studies to show both technical and clinical validation of the assay in use; and all laboratories performing IHC assays of hormone receptors in breast cancer should follow additional quality control and assurance measures as outlined in the upcoming guidelines from the American Society of Clinical Oncology and College of American Pathologists. © Journal of the National Comprehensive Cancer Network.

References Powered by Scopus

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

9221Citations
N/AReaders
Get full text

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials

6882Citations
N/AReaders
Get full text

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

5274Citations
N/AReaders
Get full text

Cited by Powered by Scopus

ImmunoRatio: A publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67

408Citations
N/AReaders
Get full text

Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: A study based on NSABP protocol B-24

317Citations
N/AReaders
Get full text

Estrogen Receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry

235Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Allred, D. C., Carlson, R. W., Berry, D. A., Burstein, H. J., Edge, S. B., Goldstein, L. J., … Wolff, A. C. (2009). NCCN Task Force Report: Estrogen receptor and progesterone receptor testing in breast cancer by immunohistochemistry. JNCCN Journal of the National Comprehensive Cancer Network. Cold Spring Publishing LLC. https://doi.org/10.6004/jnccn.2009.0079

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 32

62%

Researcher 12

23%

Professor / Associate Prof. 6

12%

Lecturer / Post doc 2

4%

Readers' Discipline

Tooltip

Medicine and Dentistry 37

65%

Agricultural and Biological Sciences 13

23%

Biochemistry, Genetics and Molecular Bi... 5

9%

Nursing and Health Professions 2

4%

Save time finding and organizing research with Mendeley

Sign up for free